Clinical trials: MS
Multiple Sclerosis
Safety and Efficacy in Pediatric MS Patients Prescribed Tysabri
The primary objective of the study is to evaluate the safety of natalizumab use in the pediatric multiple sclerosis (MS) population.
- Trial name
- NCT02137109
- Testing
- natalizumab
- Volunteers
- 400 people
- Sponsor
- Biogen
Multiple Sclerosis
Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY)
The aim of this retrospective study is to review and describe safety, tolerability and efficacy of Rebif® (subcutaneous interferon [IFN]-beta-1a) in children and adolescents, using information already recorded in medical records.
- Trial name
- REPLAY (NCT01207648)
- Testing
- Rebif®
- Where
- 18 sites in United States, Argentina and 6 more
- Volunteers
- 307 people
- Sponsor
- EMD Serono
Multiple Sclerosis (MS)
An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden
Observational data have suggested no increased risk of adverse pregnancy outcomes associated with exposure to interferon-beta (IFNB) before or during pregnancy.
- Trial name
- INFORM (NCT06053749)
- Testing
- Avonex (IFNβ-1-a, Biogen Netherlands B.V), Rebif (IFNβ-1-a, Merck Europe B.V.), Extavia (IFNβ-1-b, Novartis Europharm Limited)
- Where
- 2 sites in Finland, Sweden
- Volunteers
- 4 people
- Sponsor
- Bayer
Multiple Sclerosis
A Retrospective Study to Understand the Clinical Management of Subjects With Multiple Sclerosis at a Site in Taiwan Over the Last 10 Years
This is an observational, non comparative, non-randomised, open-label, retrospective, single centre study planned to collect the data of subjects diagnosed with multiple sclerosis (MS) as per Poser or McDonald criteria between…
- Trial name
- NCT01084798
- Where
- Taiwan
- Volunteers
- 123 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis
Multiple Sclerosis (MS) is mainly known as a disease of young to middle adulthood but approximately 5% of all MS cases worldwide involve children that are younger than 16 years.
- Trial name
- NCT00963833
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- 6 sites in Austria, Belgium and 4 more
- Volunteers
- 68 people
- Sponsor
- Bayer
Relapsing-Remitting Multiple Sclerosis
An Observational Study Evaluating Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in Multiple Sclerosis (MS) Patients
This was an observational, single arm, multicentric study conducted for the adjustment of treatment strategy and its monitoring using high-frequency and high-dosage administration of interferon-beta (Rebif) in MS subjects.
- Trial name
- NCT01142453
- Testing
- Interferon beta 1a
- Volunteers
- 231 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis (MS)
MS PATHS COVID-19 Questionnaire Data Linkage Sub-Study
The primary objective of this sub-study is to supplement the Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) dataset with coronavirus disease 2019 (COVID-19)-related health information obtained…
- Trial name
- NCT05058729
- Where
- 6 sites in United States
- Volunteers
- 1,507 people
- Sponsor
- Biogen
Multiple Sclerosis
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS)
- Trial name
- NCT01892722
- Testing
- Interferon beta-1a, Fingolimod
- Where
- 73 sites in United States, Australia and 23 more
- Volunteers
- 240 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
The primary objectives of the study are to estimate the risk of major congenital malformations (MCMs) in infants born to women with multiple sclerosis (MS) who were exposed to diroximel fumarate (DRF) at any time from 2 weeks…
- Trial name
- NCT05658497
- Testing
- Diroximel Fumarate, Avonex, Tysabri
- Where
- 8 sites in United States, Australia and 5 more
- Volunteers
- 908 people
- Sponsor
- Biogen
Multiple Sclerosis
A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)
The primary objective of the study is to compare the prevalence rate of major congenital malformations (MCM) between 2 cohorts of pregnant participants with MS who are exposed to BRIUMVI® and who are unexposed to BRIUMVI®.
- Trial name
- NCT06433765
- Testing
- No intervention
- Where
- United States
- Volunteers
- 728 people
- Sponsor
- TG Therapeutics, Inc.
Multiple Sclerosis (MS)
Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis
Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis
- Trial name
- NEOS (NCT04926818)
- Testing
- Fingolimod, Ofatumumab, Siponimod
- Where
- 51 sites in United States, Argentina and 23 more
- Volunteers
- 129 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Betaferon Use in Children and Adolescents With Multiple Sclerosis
The objective of this study is to determine efficacy, safety and tolerability of interferon beta-1b for multiple sclerosis (MS) in children and adolescents
- Trial name
- NCT03577977
- Testing
- Interferon beta-1b (Betaseron, Betaferon, BAY86-5046)
- Where
- Russia
- Volunteers
- 70 people
- Sponsor
- Bayer
Multiple Sclerosis
Quantitative Magnetic Resonance Imaging (MRI) Sub-Study of MS PATHS
The primary objective is to assess the performance of a new magnetic resonance imaging (MRI) metrics software prototype when used in radiological practice in multiple sclerosis (MS).
- Trial name
- NCT04145284
- Where
- 2 sites in United States, Germany
- Volunteers
- 6 people
- Sponsor
- Biogen
Relapsing Multiple Sclerosis
A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS)
This open label, single arm study will evaluate the PK and PD effects of fenebrutinib in children and adolescents with RMS aged between 10 and < 18 years.
- Trial name
- FENerations1 (NCT07161258)
- Testing
- Fenebrutinib
- Where
- 17 sites in Argentina, Brazil and 5 more
- Volunteers
- 12 people
- Sponsor
- Hoffmann-La Roche
Relapsing-Remitting Multiple Sclerosis
An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With Mitoxantrone
This was an open-label, multicentric, prospective, post-marketing surveillance (PMS) study to investigate whether baseline treatment with high-dose interferon beta 1a (Rebif 44 μg x 3 ), administered at a high frequency, leads to…
- Trial name
- RETURN (NCT01142518)
- Testing
- Interferon beta 1a
- Volunteers
- 86 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Progressive Multifocal Leukoencephalopathy
Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries
The primary purpose of this study is to estimate the incidence of progressive multifocal leukoencephalopathy (PML) among patients who switched to Tysabri from disease modifying therapies (DMTs), including newer DMTs (including…
- Trial name
- NCT03399981
- Testing
- Tysabri
- Where
- United States
- Volunteers
- 80,327 people
- Sponsor
- Biogen
Relapsing-Remitting Multiple Sclerosis
A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis (MS) With Interferon Beta 1a (Rebif®)
This was an open-label, multicentric, prospective, post-marketing surveillance (PMS) study on the extent to which subject compliance is influenced by use of a variable titration regimen at the start of treatment of relapsing MS…
- Trial name
- TOURIMS (NCT01142492)
- Testing
- Interferon beta-1a
- Volunteers
- 403 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Relapsing-remitting Multiple Sclerosis
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)
This double-blind, double-dummy study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with RRMS aged between 10 and < 18 years over a flexible duration.
- Trial name
- Operetta 2 (NCT05123703)
- Testing
- Ocrelizumab, Fingolimod
- Where
- 71 sites in United States, Argentina and 23 more
- Volunteers
- 188 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis, Diabetes
An Observational Post-Marketing Safety Registry of Sativex®
The purpose of this registry is to monitor safety outcomes of patients who are receiving Sativex® for Multiple Sclerosis (MS) spasticity and for off-label indications in the United Kingdom (UK), Germany and Sweden.
- Conditions
- Multiple Sclerosis, Diabetes, Cancer, Neuropathic Pain
- Trial name
- NCT02073474
- Testing
- Sativex®
- Volunteers
- 978 people
- Sponsor
- Jazz Pharmaceuticals
Relapsing Multiple Sclerosis
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
The primary objective of this study is to demonstrate that the incidence of progressive multifocal Leukoencephalopathy (PML) in natalizumab-treated participants who do not have detectable antibodies to John Cunningham virus (JCV)…
- Trial name
- STRATIFY-2 (NCT01070836)
- Testing
- natalizumab
- Where
- 478 sites in United States, Puerto Rico
- Volunteers
- 35,895 people
- Sponsor
- Biogen